Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With PRESERVED Ejection Fraction Heart Failure
Phase: PHASE4
Conditions: Chronic Heart Failure With Preserved Systolic Function
Sponsor: Saint Luke's Health System

EFFECTS OF DAPAGUFLOZIN ON BIOMARKERS, SYMPTOMS AND FUNCTIONAL STATUS IN 
PATIENTS WITH PRESERVED EJECTION FRACTION HEART fAILURE (PRESERVED-HF TRIAL) 
Protocol Number: D1690C00053 
PRESERVED-HF Protocol v3.0 
Page 1 of67 
Version Date March 20, 2020
Protocol
NCT03030235